Repligen, established in 1981 and headquartered in the United States, operates within the manufacturing sector, particularly focusing on pharmaceuticals, biotech, and medical devices. The company has a workforce ranging from 1,001 to 5,000 employees and reported a revenue of approximately $707 million. Repligen's published documents highlight its expertise in bioprocessing and analytical methods, particularly in the context of protein concentration measurement. One document discusses the evaluation of a variable-pathlength spectrophotometer, emphasizing its advantages over traditional fixed-pathlength instruments for determining protein concentrations in bioprocessing applications. This technology allows for precise measurements across a broader range of sample concentrations, which is critical for process optimization and formulation in the pharmaceutical industry. Additionally, Repligen's research articles and thought leadership pieces contribute to the discourse on advanced analytical techniques and their applications in bioprocessing, reflecting the company's commitment to innovation and scientific advancement in the field.